title: Comparative pharmacokinetics and pharmacodynamics of tablet, suspension and paste formulations of atenolol in cats.
abstract: This study compared the pharmacokinetic and pharmacodynamic profiles of an extemporaneously prepared (compounded) atenolol paste and suspension for oral administration, against the commercially available divided tablet in healthy cats. Eleven healthy cats (mean: age 4 ± 0.4 year, weight 5.0 ± 0.7 kg) were dosed twice-daily with 12.5 mg atenolol (tablet, paste or suspension) for 7 days in a randomized cross-over design with a 7-day wash-out period. On day 7, an electrocardiogram was performed before and immediately after stress provocation (jugular venipuncture) at prestudy screening, and at 2, 6 and 12 h after morning dosing. Systolic arterial blood pressure (BP) was assessed following the second electrocardiogram. Plasma was collected at prestudy screening, and at 1, 2, 6 and 12 h to measure atenolol plasma concentrations. Mean atenolol dose was 2.5 mg/kg (range: 2.1-3.3 mg/kg). Stress-induced rise in heart rate was attenuated (P < 0.05) at every time point compared to baseline for all formulations. Although the paste significantly attenuated stress-induced elevation in heart rate at all time points, the effect was not consistently equivalent to the tablet. The BP was not altered (P > 0.05) at any time point by any formulation. In conclusion, there were no significant differences (P > 0.05) in any of the pharmacokinetic parameters or pharmacodynamic profiles of the paste and suspension compared to the commercially available tablet.
authors: School of Veterinary Science, The University of Queensland, Gatton, Qld, Australia.
authors: K H
authors: KH
authors: Khor
authors: F E
authors: FE
authors: Campbell
authors: B G
authors: BG
authors: Charles
authors: R L G
authors: RL
authors: Norris
authors: R M
authors: RM
authors: Greer
authors: M J
authors: MJ
authors: Rathbone
authors: P C
authors: PC
authors: Mills
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001262:Atenolol / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D001794:Blood Pressure; D002415:Cats / Q000097:blood*; D018592:Cross-Over Studies; D004304:Dosage Forms; D005260:Female; D006207:Half-Life; D006339:Heart Rate; D008297:Male; D013565:Sympatholytics / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology
chemical_list: D004304:Dosage Forms; D013565:Sympatholytics; D001262:Atenolol